Amryt Announces 22% growth in FY 2021 Revenues to $222.5M

Issuing FY 2022 revenue guidance of $260M - $270M, representing 17%-21% YoY growth Cash of $113.0M at December 31, 2021 Board approves stock repurchase program of up to $30M 8th consecutive quarter of positive EBITDA generation 32% YoY growth in metreleptin revenues Successful bioavailability study supporting development of Mycapssa® for carcinoid symptoms in NET Global NET market opportunity is estimated to be approx. $1.9bn*

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here